The results of the immunohistochemical staining demonstrated that SPRR3 was upregulated in the tissue samples of more than half of the GBM patients (72.7%) and the methylation level of SPRR3 was correlated with the clinical outcome in glioma patients validated by DNA methylation profile analysis. This evidence concerns the gene SPRR3 and glioblastoma.